胃癌中对免疫检查点抑制剂的耐药性
Kai Liu1, Shiman Yuan1, Chenyu Wang2
1The Clinical Medical College, Guizhou Medical University, Guiyang, China.
Frontiers in pharmacology
|November 29, 2023
概括
了解免疫抵抗是改善胃癌治疗的关键. 本综述探讨了瘤如何对免疫检查点抑制剂 (ICI) 产生耐药性,从而阻碍患者的反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 胃癌 (GC) 仍然是癌症死亡的主要原因,尽管诊断方面取得了进展.
- 免疫检查点抑制剂 (ICI) 为晚期GC提供了新的治疗途径,但显示出有限的持久反应.
- 对ICI的抗性是一个重大挑战,需要对其机制有更深入的了解.
研究的目的:
- 审查和总结胃癌中对ICI产生初级和获得性耐药性的内部和外部机制.
- 突出了解GC免疫抵抗的关键需求,以改善治疗结果.
- 根据当前的研究,讨论潜在的抵抗机制.
主要方法:
- 文献综述侧重于胃癌中对免疫检查点抑制剂的耐药性机制.
- 分析导致抗性的内部 (瘤内在) 和外部 (瘤微环境) 因素.
- 综合当前关于胃癌免疫抵抗的研究结果.
主要成果:
- 确定了各种内部和外部因素,这些因素有助于GC中对ICI的初级和获得性耐药性.
- 强调对GC免疫抵抗机制的理解不足.
- 突出了晚期GC患者对ICI的有限持久反应率.
结论:
- 澄清GC免疫抵抗机制对于提高治疗疗效和临床益处至关重要.
- 对抗性途径的进一步研究对于开发更有效的胃癌免疫疗法至关重要.
- 解决ICI耐药性对于改善晚期胃癌患者的治疗结果至关重要.
相关概念视频
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K